At Vaxxinova, we develop, manufacture, and sell veterinary vaccines including our Newport Laboratories brand of whole-cell bacterins and viral vaccines, and vaccines based upon our proprietary SRP® technology.
Each vaccine you receive is fully supported by advanced molecular diagnostics and a team of qualified individuals with years of lab experience.
Guiding the Way for better animal health.
Maintaining the health of your animals is central to the success of any livestock operation Vaxxinova works to ensure that veterinarians and livestock producers are equipped with the preventative, diagnostic, and educational tools necessary to ensure peak performance. The livestock industry changes quickly, and these changes often bring unique disease challenges.
Our use of molecular biology techniques such as gene sequencing and DNA fingerprinting save valuable time in diagnosing complex problems. By genetically selecting specific virus strains, our team can create vaccines specifically targeted to the issues facing your animals. The world of animal health continues to evolve, and you will find Vaxxinova on the leading edge.
Staying on top of disease prevention and overall heard health issues is no small feat. Vaxxinova puts you on a winning team in this battle. No matter what challenges today’s changing environment brings, you can rest assured that the team at Vaxxinova is working to discover and implement the most cost-effective, cutting-edge tools to help you solve the problem.
Our Core Strengths
HISTORY OF VAXXINOVA
Vaxxinova US is a division of Vaxxinova International, who’s current network comprises production, research & development, sales and diagnostic facilities in multiple countries: Brazil, Chile, Germany, Italy, Japan, Jordan, Norway, the Netherlands, Thailand and the USA. Vaxxinova is part of the family-owned EW Group.
The EW Group specializes in animal genetics, animal nutrition and animal health, operates in over 100 countries and records consistent international growth. Its positive outlook and global orientation have led to an independent and significantly stable position in the market and a steady expansion. As the EW Group is family-owned, which is rare in this sector these days, highly progressive strategies for the future can be pursued, based on long-term investment strategies.
Vaxxinova acquired Epitopix in 2018 and Newport Laboratories in 2021, and today operates as Vaxxinova US. Both entities have storied history for innovation, ground-breaking technology, and industry leading diagnostic laboratories.
Epitopix, which began as the laboratory service division of Willmar Poultry Company (WPC) in Willmar, Minnesota. During the 1980s, WPC began to seek innovative ways to improve the health of its turkey breeding stock. Epitopix, LLC was formed in 2002 to commercialize SRP technology, and to discover new vaccine technologies that improve animal health and human food safety.
Newport Laboratories was founded in 1996 in Worthington, Minnesota. It quickly became the industry leader in autogenous (custom) vaccines for cattle and swine, as well as a state-of-the-art diagnostic laboratory.
Discovery and development continue today, to bring novel vaccine products to additional markets including livestock and poultry. Epitopix owns intellectual property rights to all of its discoveries and has out-licensed SRP Technology development rights for human medical applications to Syntiron, LLC.
With complementary portfolios, the acquisition allowed for new synergies for producers and veterinarians.
VAXXINOVA US CONTINUES TO BE PRIVATELY HELD, AND CURRETNLY HOLDS TWO USDA ESTABLISHMENT LICENSES (NO. 365 & NO. 455) FOR THE MANUFACTURING OF VETERINARY BIOLOGICALS.